Skip to main content
Signal8
Launch Terminal

AGENUS INC (AGEN)

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Agenus Inc. logo

Agenus Inc.

NASDAQ:AGENHealthcare
-3.53%$6.84
AH$6.78-0.92%vs close
Mkt Cap$308.91M
Float42.23M
O/S45.16M
Vol
$ Vol
RVOL
Inst Own31.5%
SI16.6%
Earnings
Dilution
Agenus Inc. logoNASDAQ:AGEN$6.84-3.53%
Upcoming Catalysts
Phase Distribution
31 lead-sponsored trials·2 active·15 completed
Phase 19
Phase 1/23
Phase 213
Phase 34
Not applicable2
(31 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

    autologous human tumor-derived HSPPC-96

    Renal Cell Carcinoma

    Enrollment
    650
    Start
    Jun 2000
    Primary Completion
    Apr 2007
    Completion
    Apr 2007
    NCT00033904
  • Phase 3
    Completed

    Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

    HSPPC-96 or Oncophage

    Malignant Melanoma

    Enrollment
    350
    Start
    Mar 2002
    Primary Completion
    Dec 2005
    Completion
    Dec 2005
    NCT00039000
  • Phase 3
    Terminated

    Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer

    HSPPC-96

    Kidney Cancer, Renal Cell Carcinoma

    Enrollment
    600
    Start
    May 2005
    Primary Completion
    Mar 2006
    Completion
    Mar 2006
    NCT00126178
  • Phase 3
    Withdrawn

    Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

    Balstilimab (BAL), Topotecan

    Advanced Cancer, Metastatic Cervical Cancer

    Enrollment
    0
    Start
    Aug 2021
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT04943627
  • Phase 2
    Terminated

    AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

    Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.

    Leukemia, Myeloid, Chronic

    Enrollment
    40
    Start
    Mar 2003
    Primary Completion
    Apr 2006
    Completion
    Apr 2006
    NCT00058747
  • Phase 2
    Completed

    A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

    autologous human tumor-derived HSPPC-96

    Lymphoma, Follicular, Lymphoma, Small Lymphocytic

    Enrollment
    35
    Start
    Mar 2000
    Primary Completion
    Jun 2005
    Completion
    Jun 2005
    NCT00081809
  • Phase 2
    Terminated

    Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

    autologous human tumor-derived HSPPC-96

    Renal Cell Carcinoma

    Enrollment
    40
    Start
    Jul 2002
    Primary Completion
    Dec 2005
    Completion
    Dec 2005
    NCT00082459
  • Phase 2
    Completed

    Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

    HSPPC-96

    Non-Small-Cell Lung Carcinoma, Lung Cancer +1

    Enrollment
    20
    Start
    Sep 2003
    Primary Completion
    Nov 2007
    Completion
    -
    NCT00098085
  • Phase 2
    Terminated

    Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

    HSPPC-96

    Renal Cell Carcinoma

    Enrollment
    12
    Start
    Jan 2010
    Primary Completion
    Jun 2012
    Completion
    Jun 2012
    NCT01147536
  • Phase 2
    Completed

    Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

    HerpV and QS-21, Placebo

    Herpes Simplex Type 2

    Enrollment
    80
    Start
    Oct 2012
    Primary Completion
    Sep 2013
    Completion
    Jan 2015
    NCT01687595
  • Phase 2
    Terminated

    Study of AGEN1884 With Pembrolizumab in 1L NSCLC

    AGEN1884 in combination with pembrolizumab

    NSCLC Stage IV

    Enrollment
    2
    Start
    Oct 2017
    Primary Completion
    May 2018
    Completion
    Mar 2019
    NCT03411473
  • Phase 2
    Terminated

    RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

    AGEN2034, AGEN1884

    Cervical Cancer

    Enrollment
    211
    Start
    Jun 2019
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT03894215
  • Phase 2
    Withdrawn

    AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

    AGEN2034, AGEN1884

    Angiosarcoma

    Enrollment
    0
    Start
    Feb 2021est.
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04607200
  • Phase 2
    Withdrawn

    A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

    Balstilimab, Balstilimab + Zalifrelimab

    Cervical Cancer

    Enrollment
    0
    Start
    Oct 2021
    Primary Completion
    Dec 2024est.
    Completion
    Dec 2024est.
    NCT05033132
  • Phase 2
    Terminated

    A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

    Botensilimab, Balstilimab

    Advanced Melanoma

    Enrollment
    150
    Start
    Dec 2022
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT05529316
  • Phase 2
    Active, not recruiting

    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

    Botensilimab, Balstilimab

    Metastatic Colorectal Cancer

    Enrollment
    234
    Start
    Nov 2022
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2029est.
    NCT05608044
  • Phase 2
    Completed

    A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

    Botensilimab, Gemcitabine

    Metastatic Pancreatic Ductal Adenocarcinoma

    Enrollment
    81
    Start
    Mar 2023
    Primary Completion
    Jan 2026
    Completion
    Jan 2026
    NCT05630183
  • Phase 1/2
    Completed

    AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

    Zalifrelimab

    Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

    Enrollment
    89
    Start
    Apr 2016
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT02694822
  • Phase 1/2
    Completed

    A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

    AGEN2034

    Advanced Cancer, Cervical Cancer

    Enrollment
    211
    Start
    Apr 2017
    Primary Completion
    Jun 2022
    Completion
    Jun 2022
    NCT03104699
  • Phase 1/2
    Completed

    A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

    Zalifrelimab, Balstilimab

    Cervical Cancer

    Enrollment
    175
    Start
    Dec 2017
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT03495882
  • Phase 1
    Completed

    Trial Evaluating Safety, Tolerability and Immune Response of AG-707

    AG-707

    Genital Herpes

    Enrollment
    35
    Start
    Mar 2006
    Primary Completion
    -
    Completion
    -
    NCT00231049
  • Phase 1
    Completed

    Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma

    Aroplatin

    Malignancies, B-Cell Lymphoma

    Enrollment
    21
    Start
    Mar 2006
    Primary Completion
    Jun 2008
    Completion
    -
    NCT00316511
  • Phase 1
    Terminated

    Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer

    AutoSynVax™ vaccine

    Advanced Cancer

    Enrollment
    3
    Start
    Jan 2017
    Primary Completion
    Dec 2018
    Completion
    Dec 2019
    NCT02992977
  • Phase 1
    Completed

    Phase 1a Study to Evaluate Immunogenicity of ASV®

    ASV® AGEN2017 + QS-21 Stimulon® adjuvant

    Solid Tumor, Adult

    Enrollment
    3
    Start
    May 2019
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT03673020
  • Phase 1
    Active, not recruiting

    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

    Botensilimab, Balstilimab

    Advanced Cancer, Angiosarcoma +6

    Enrollment
    499
    Start
    Mar 2019
    Primary Completion
    Jan 2025
    Completion
    Dec 2027est.
    NCT03860272

1-25 of 31

Search ClinicalTrials.gov for “Agenus”